Yttrium Y-90 clivatuzumab tetraxetan

DB15368InvestigationalProtein Based Therapies

Yttrium Y-90 clivatuzumab tetraxetan is under investigation in clinical trial NCT00603863 (Safety and Efficacy Study of Different Doses of 90Y-hPAM4 Combined With Gemcitabine in Pancreatic Cancer).

Mechanism: Pharmacologically active on Mucin-5AC
Curator reviewed
Also known as: 90Y-HPAM4 · 90Y-hPAMA4 · HPAM4-DOTA · PAN-CIDE · Yttrium (90y) clivatuzumab tetraxetan
Code names: IMMU-107

Resolves to

Compound

UNII2L271110EDCAS943976-23-6

Targets

P98088MUC5AC

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Yttrium Y-90 clivatuzumab tetraxetan, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account